Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
3
50%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

unknown117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

BAY88-8223, Dose Finding Study in Patients With HRPC

NCT00337155
completedphase_2

BAY88-8223, Does Response Study in HRPC Patients

NCT00667199
completedphase_1

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

NCT01798108
completedphase_3

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

NCT01618370
unknown

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

NCT01516762
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00337155Phase 2

BAY88-8223, Dose Finding Study in Patients With HRPC

Completed
NCT00667199Phase 2

BAY88-8223, Does Response Study in HRPC Patients

Completed
NCT01798108Phase 1

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Completed
NCT01618370Phase 3

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Completed
NCT01516762

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Unknown
NCT00459654Phase 2

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6